CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D009091: Mucormycosis NIH

(Synonyms: Mucormycosis)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1479 Isavuconazonium sulfate Wiki 0.71
drug551 COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection Wiki 0.71

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D020096 Zygomycosis NIH 1.00
D001228 Aspergillosis NIH 0.71

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects

The purpose of this study is to evaluate the safety, tolerability, and efficacy of isavuconazonium sulfate in pediatric participants.

NCT03816176 Invasive Mucormycosis Invasive Aspergillosis Drug: Isavuconazonium sulfate Drug: Isavuconazonium sulfate
MeSH:Aspergillosis Mucormycosis Zygomycosis

Primary Outcomes

Description: An AE is any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product.

Measure: Safety assessed by Adverse Events (AEs)

Time: Up to 240 days

Description: Number of participants with potentially clinically significant vital sign values

Measure: Number of participants with vital sign abnormalities and /or adverse events

Time: Up to 84 days

Description: A 12-lead, resting ECG will be recorded after participant has remained supine for at least 5 minutes. The results (normal, abnormal not clinically significant, abnormal clinically significant) are to be recorded

Measure: Safety assessed by 12- lead electrocardiogram (ECG)

Time: Up to 84 days

Description: Number of participants with potentially clinically significant laboratory values

Measure: Number of participants with laboratory value abnormalities and/or adverse events (AEs)

Time: Up to 84 days

Description: Each participant will be classified as either a death or alive

Measure: All-cause mortality through Day 42

Time: Up to 42 days

Secondary Outcomes

Description: Each participant will be classified as either a death or alive

Measure: All-cause mortality through Day 84

Time: Up to 84 days

Description: Each participant will be classified as either a death or alive

Measure: All-cause mortality at End of Treatment (EOT)

Time: Up to 180 days

Description: Overall response through day 42 will be based on clinical, mycological, and radiological response

Measure: Overall response through Day 42

Time: Up to 42 days

Description: Overall response through day 84 will be based on clinical, mycological, and radiological response

Measure: Overall response through Day 84

Time: Up to 84 days

Description: Overall response through EOT will be based on clinical, mycological, and radiological response

Measure: Overall response at EOT

Time: Up to 180 days

Description: Each participant will be assessed for changes in clinical sign and symptoms of infection(s)

Measure: Clinical response through Day 42

Time: Up to 42 days

Description: Each participant will be assessed for changes in clinical sign and symptoms of infection(s)

Measure: Clinical response through Day 84

Time: Up to 84 days

Description: Each participant will be assessed for changes in clinical sign and symptoms of infection(s)

Measure: Clinical response at EOT

Time: Up to 180 days

Description: Each participant will be assessed for radiological evidence of fungal disease

Measure: Radiological response through Day 42

Time: Up to 42 days

Description: Each participant will be assessed for radiological evidence of fungal disease

Measure: Radiological response through Day 84

Time: Up to 84 days

Description: Each participant will be assessed for radiological evidence of fungal disease

Measure: Radiological response at EOT

Time: Up to 180 days

Description: Each participant will be assessed for mycological evidence of fungal disease

Measure: Mycological response through Day 42

Time: Up to 42 days

Description: Each participant will be assessed for mycological evidence of fungal disease

Measure: Mycological response through Day 84

Time: Up to 84 days

Description: Each participant will be assessed for mycological evidence of fungal disease

Measure: Mycological response at EOT

Time: Up to 180 days

Description: Ctrough will be recorded from the pharmacokinetic (PK) plasma samples collected

Measure: Pharmacokinetics of isavuconazole in plasma: trough concentration (Ctrough)

Time: Up to 84 days


HPO Nodes